Pooled analysis of the efficacy and safety from two non-interventional studies of fluticasone propionate/formoterol pMDI

V. Backer (Copenhagen, Denmark), O. Schmidt (Koblenz, Germany), B. Langer-Brauburger (Limburg, Germany), T. Schmidt (Limburg, Germany), C. Bennett (Cambridge, United Kingdom), D. Lindner (Limburg, Germany), S. Cuadripani (Cambridge, United Kingdom), B. Grothe (Cambridge, United Kingdom), T. Overend (Cambridge, United Kingdom)

Source: International Congress 2018 – New developments in the treatment of asthma
Session: New developments in the treatment of asthma
Session type: Thematic Poster
Number: 1025
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Backer (Copenhagen, Denmark), O. Schmidt (Koblenz, Germany), B. Langer-Brauburger (Limburg, Germany), T. Schmidt (Limburg, Germany), C. Bennett (Cambridge, United Kingdom), D. Lindner (Limburg, Germany), S. Cuadripani (Cambridge, United Kingdom), B. Grothe (Cambridge, United Kingdom), T. Overend (Cambridge, United Kingdom). Pooled analysis of the efficacy and safety from two non-interventional studies of fluticasone propionate/formoterol pMDI. 1025

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Real-world study to evaluate the safety and effectiveness of fluticasone propionate/formoterol (FP/FORM) in patients with asthma
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017


Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD
Source: Eur Respir J 2014; 43: 763-772
Year: 2014



Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma
Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies
Year: 2020


Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021
Year: 2021



A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budesonide plus formoterol as separate inhalers
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Effectiveness and safety of fluticasone propionate/salmeterol 250/50mcg administered once daily to patients with persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 309s
Year: 2004

A pilot study comparing tiotropium to salmeterol plus fluticasone in moderate COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010


Safety and efficacy of fluticasone furoate/vilanterol trifenatate (FFVI) in COPD patients
Source: Annual Congress 2010 - Bronchodilators in airways disease
Year: 2010

Efficacy and safety of budesonide/formoterol comparing with budesonide and theophylline in Japanese adult patients with asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008

Comparison of the efficacy and safety of budesonide administered via Clickhaler® or Turbuhaler®
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011

Efficacy and safety of fluticasone furoate (FF)/vilanterol (VI) compared with fluticasone propionate/salmeterol combination (FP/SAL) in adults and adolescents with persistent asthma
Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma
Year: 2012

Equivalent bone safety and better efficacy of fluticasone propionate compared to nedocromil sodium in asthmatic children. Results of a 2-year randomized study
Source: Eur Respir J 2002; 20: Suppl. 38, 219s
Year: 2002

A post-marketing study to evaluate the safety and tolerability of a non-chlorofluorocarbon salbutamol inhaler in asthmatic patients in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 78s
Year: 2002

The efficacy and safety of fluticasone propionate on Chinese asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 97s
Year: 2001